Drugs / lintuzumab
Trials 14 · a red edge is where a trial was stopped
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lintuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002800 ↗ |
| Known as | 90Y-MOAB HuM195 | “yttrium-90-labeled humanized monoclonal antibody M195 (90Y-MOAB HuM195)” NCT00002890 ↗ |
| Known as | HuM-195/rGel | “The goal of this clinical research study is to find the highest safe dose of the anti-CD33 immunotoxin HuM-195/rGel that can be given to patients with advanced myeloid malignancies.” NCT00038051 ↗ |
| Known as | HuM195 | “A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies.” PMID 19557623 ↗ Aug 20094“Lintuzumab (SGN-33; HuM195) is a humanized monoclonal antibody directed against CD33, which is expressed on the majority of myeloblasts in acute myeloid leukemia.” PMID 22801961 ↗ Jul 2012 “In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses” NCT02575963 ↗ “yttrium-90-labeled humanized monoclonal antibody M195 (90Y-MOAB HuM195)” NCT00002890 ↗ |
| Known as | M195 | “yttrium-90-labeled humanized monoclonal antibody M195 (90Y-MOAB HuM195)” NCT00002890 ↗ |
| Action | Deplete | “The immunotoxin is designed to selectively destroy myeloid leukemia cells.” NCT00038051 ↗ |
| Modality | Monoclonal antibody | “humanized anti-CD33 monoclonal antibody” NCT00002609 ↗ |
| Route | Intravenous | “All patients receive a single intravenous dose of 90Y-MOAB HuM195.” NCT00002890 ↗ |
| Target | CD33 | “anti-CD33 monoclonal antibody” NCT00002609 ↗ |